<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727192</url>
  </required_header>
  <id_info>
    <org_study_id>Gullestad</org_study_id>
    <nct_id>NCT02727192</nct_id>
  </id_info>
  <brief_title>Effect of Treatment of Sleep Apnea in Patients With Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>Sleep Disordered Breathing in Patients With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Health Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac rhythm disturbance in adults, with&#xD;
      prevalence expected to rise significantly the coming decades. The occurrence of AF is&#xD;
      associated with significantly increased mortality as well as morbidity of which&#xD;
      cerebrovascular accidents is the most important. Unfortunately treatment options remain&#xD;
      limited. Anti-arrhythmic drugs are widely used but have limited efficacy and the potential&#xD;
      for toxicity and adverse events are recognized. Recent year's catheter ablation of AF&#xD;
      continues to gain acceptance for symptomatic treatment, but recurrence rate are high with&#xD;
      need for continuous medication. Thus there is a need to better understand what causes&#xD;
      development and triggers episodes of AF as well to introduce new treatment options.&#xD;
      Cardiometabolic factors such as obesity, inactivity and sleep apnea (SA) have therefore&#xD;
      gained interest. Many patients with AF have chronic sleep apnea, and in the present study the&#xD;
      investigators want to explore the interaction between SA and AF. The hypothesis of the&#xD;
      present study is that SA may trigger AF and that treatment of SA will reduce the overall&#xD;
      burden of AF as well as reduce the recurrence of AF after pulmonary vein ablation. To test&#xD;
      the hypothesis the investigators will implant a Reveal device that continuously records the&#xD;
      hearts rhythm of 100 patients with paroxysmal AF and concomitant SA. Initially the influence&#xD;
      of SA on onset of AF will be examined, and the patients will then be randomized to treatment&#xD;
      of SA or not and the influence on total AF burden recorded both before and after ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the present project the investigators have established a research team from 2 different&#xD;
      university hospitals. This team, including high ranked, internationally renowned scientist&#xD;
      from both clinical and basic sciences, will make a framework for PhD candidates and will&#xD;
      ensure the patient cohort. Patients with paroxysmal AF and SA will be examined with an&#xD;
      extensive diagnostic battery including advanced cardiac imaging tools allowing a proper&#xD;
      description of the heart. Then a Reveal that continuously monitor the rhythm of the heart&#xD;
      will be inserted, allowing the influence of SA, physical activity, inflammatory parameters,&#xD;
      and other external variables on total AF burden to be examined. The patients will then be&#xD;
      randomized to treatment of SA with a CPAP or not, and the AF burden recorded 6 months before&#xD;
      ablation and 6 months after.&#xD;
&#xD;
      The present investigations carried out, are expected to results in better understanding of&#xD;
      the interaction between AF and SA and may lay the scientific basis for better diagnostic and&#xD;
      therapeutic approaches for patients with AF. In addition, given the advantage of continuous&#xD;
      RevealÂ® recording of the patient's heart rhythm, the present study will examine possible&#xD;
      triggers of AF such as activity level and inflammatory substances, and examine the role of&#xD;
      structural abnormalities in the heart as assessed by echocardiography for the triggering of&#xD;
      AF episodes. An overall aim is therefore a better phenotyping of the patient which could aid&#xD;
      in a more person-specific treatment approach, with direct consequences both for the&#xD;
      individual patient and for the society.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2016</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AF Burden</measure>
    <time_frame>Baseline (pre-randomization) was the first month of loop recorder data collection and was compared to the last three months of the intervention period.</time_frame>
    <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last three months of the five month intervention period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AF Burden</measure>
    <time_frame>Baseline to the last month of intervention period</time_frame>
    <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last month of the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AF Burden</measure>
    <time_frame>Comparing Baseline to the last five months of the intervention period</time_frame>
    <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last five months of the intervention period (the whole intervention period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With More Than 25% Reduction in AF Burden</measure>
    <time_frame>Baseline to last three months of the intervention</time_frame>
    <description>Difference between PAP treatment and usual care in the proportion of patients with at least 25% reduction of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last three months of the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Recurrence Rate After Ablation, as Measured by Loop Recorder</measure>
    <time_frame>12 months</time_frame>
    <description>Change of recurrence rate after ablation, as measured by loop recorder, after 6 months post ablation and after 12 months post ablation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AF Symptoms as Assessed by Atrial Fibrillation Severity Scale (AFSS)</measure>
    <time_frame>6 months, 12 months and 18 months</time_frame>
    <description>Change in AF symptoms between CPAP treatment and usual care. The questionnaire quantifies three domains of AF: event frequency (score 1-10), duration (score 1-10), and global episode severity (score 1-10). The total AF burden is calculated from the modified sum of the frequency, duration, and severity of AF (score 3-30, with higher scores indicating greater AF burden ). In addition, the AFSS assesses a symptom score based on seven items asking how bothered patients are by specified symptoms (score 0-35). Global well-being is a visual analogue scale ranging from 1 to 10 (10 indicating the best possible life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL) as Assessed by Medical Outcomes Study 36-item Short-Form Health Survey (SF-36)</measure>
    <time_frame>Assessed at baseline, 6 months, 12 months and 18 months, baseline and 6 months reported.</time_frame>
    <description>Difference between CPAP and usual care in QoL as assessed by SF36, Version 1.2. Item scores are transformed into the Physical and Mental Component Summary scores (PCS and MCS). Scores range from 0 to 100, with higher scores indicating a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Quality and Symptoms of Sleep Apnea: Epworth Sleepiness Scale (ESS) Score</measure>
    <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported</time_frame>
    <description>Difference between PAP treatment and usual care in Change in daytime sleepiness as measured using the Epworth Sleepiness Scale (ESS) score, with scores ranging from 0 to 24 (most sleepy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symptoms of Obstructive Sleep Apnea Assessed by the Berlin Questionnaire.</measure>
    <time_frame>6 months, 12 months and 18 months</time_frame>
    <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the Berlin Questionnaire. Positive scores in two or more categories suggest a high risk of OSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symptoms of Sleep Apnea Using the Functional Outcomes of Sleep Questionnaire (FOSQ)</measure>
    <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported.</time_frame>
    <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the Functional Outcomes of Sleep Questionnaire (FOSQ). Score range is 5-20 Points, with higher scores indicating better functional status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symptoms of Sleep Apnea Measured by the STOP-Bang</measure>
    <time_frame>6 months, 12 months and 18 months</time_frame>
    <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the STOP-Bang Questionnaire. Score between 0-8. A score of â¥3 suggest risk for OSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported.</time_frame>
    <description>Difference between PAP treatment and usual care in change of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction</measure>
    <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported.</time_frame>
    <description>Difference between PAP treatment and usual care in change of left ventricular ejection fraction as assessed by ecco</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Cardiac Marker NT-proBNP.</measure>
    <time_frame>6 months, 12 months. Baseline and 6 months reported.</time_frame>
    <description>Difference between PAP treatment and usual care in change of Cardiac marker of NT-proBNP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the Effect of SA Treatment on Gene Expression of White Blood Cells.</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Examine the effect of SA treatment on gene Expression of white blood cells. Is paroxysmal AF Associated with specific gene Expression patterns? Examine the influence of SA treatment on the pattern of gene Expression and if this is related to reduction of atrial fibrillation burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine if Onset of Paroxysmal AF is Associated With Specific Activity Patterns, as Assessed by Garmin Vivofit2/3, Activity Recording</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Examine if onset of paroxysmal AF is Associated with specific Activity patterns, as assessed by garmin Vivofit2/3, Activity recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Composition as Assessed by Bioelectric Impedance Analysis (BIA) (Tanita)</measure>
    <time_frame>Baseline to follow up 6 months</time_frame>
    <description>Change in body composition (BMI) as assessed by Bioelectric Impedance Analysis (BIA) (Tanita)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Test as Assessed by Spirometry</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Lung function test as assessed by spirometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Sleep Disordered Breathing</condition>
  <condition>Sleep Apnea</condition>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PAP-therapy (CPAP or ASV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No sleep apnea treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAP (CPAP or ASV)</intervention_name>
    <description>Patients will be randomized to treatment of Sleep Apnea with a CPAP or control</description>
    <arm_group_label>PAP-therapy (CPAP or ASV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Patients with paroxysmal AF scheduled for first or second catheter ablation&#xD;
&#xD;
          -  Moderate-to-severe SA defined as an AHI â¥15/h (OSA and/or CSA)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable patients&#xD;
&#xD;
          -  Patients with left ventricular ejection fraction (LV-EF) &lt; 45%&#xD;
&#xD;
          -  Unstable coronary artery disease, myocardial infarction or PCI within 3 months prior&#xD;
             to the study&#xD;
&#xD;
          -  Bypass surgery within 6 months prior to the study&#xD;
&#xD;
          -  Patients with TIA or stroke within the previous 3 months&#xD;
&#xD;
          -  BMI &gt; 40kg/m2&#xD;
&#xD;
          -  Drowsy drivers and/or sleepy patients with ESS (Epworth Sleepiness Score) &gt; 15&#xD;
&#xD;
          -  Patients with interstitial lung diseases, severe obstructive lung defects, and&#xD;
             thoracic myopathies or severe obstructive lung defects with FEV1 &lt; 50% of predicted&#xD;
&#xD;
          -  Oxygen saturation &lt; 90% at rest during the day&#xD;
&#xD;
          -  Poor compliance&#xD;
&#xD;
          -  Patients with single chamber pacemaker (or ICD)&#xD;
&#xD;
          -  Current use of PAP therapy&#xD;
&#xD;
          -  Patients using amiodarone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Gullestad, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <results_first_submitted>February 24, 2021</results_first_submitted>
  <results_first_submitted_qc>May 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Gullestad</investigator_full_name>
    <investigator_title>Professor MD</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>CPAP</keyword>
  <keyword>Sleep apnea</keyword>
  <keyword>Sleep disordered breathing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02727192/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02727192/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>109 patients with paroxysmal atrial fibrillation and moderate to severe sleep apnea were included in the study and randomized to PAP-therapy or control. One patient refused further participation and was not included in the analysis. 108 patients were therefore included in the full set analysis.&#xD;
21 patients without sleep apnea or mild sleep apnea (AHI&lt;15) were included as a reference group.&#xD;
Therefore, 130 patients were included in the study, but only 109 were included for randomization.</recruitment_details>
      <pre_assignment_details>Before inclusion patients were invited to a CPAP mask tolerance test. Patients who complied with the treatment were invited to be included in the study.&#xD;
All patients were randomized to CPAP. In the CPAP group, one patient had CPAP treatment-emergent central SA shortly after randomization and was therefore switched to ASV.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CPAP-therapy</title>
          <description>CPAP-therapy (Continous Positive Airway Pressure)</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>No sleep apnea treatment (usual care)</description>
        </group>
        <group group_id="P3">
          <title>ASV-therapy</title>
          <description>ASV-therapy (Adaptive Servo-Ventilation)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PAP-therapy (CPAP or ASV)</title>
          <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>No sleep apnea treatment (usual care)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="7.4"/>
                    <measurement group_id="B2" value="62.1" spread="7.8"/>
                    <measurement group_id="B3" value="62.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in AF Burden</title>
        <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last three months of the five month intervention period.</description>
        <time_frame>Baseline (pre-randomization) was the first month of loop recorder data collection and was compared to the last three months of the intervention period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AF Burden</title>
          <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last three months of the five month intervention period.</description>
          <units>percentage of time in AF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="8.3"/>
                    <measurement group_id="O2" value="5.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last three months of intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="6.5"/>
                    <measurement group_id="O2" value="4.3" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.520</p_value>
            <p_value_desc>A two-sided significance level of 5% was considered to indicate statistical significance.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in AF Burden</title>
        <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last month of the intervention period.</description>
        <time_frame>Baseline to the last month of intervention period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AF Burden</title>
          <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last month of the intervention period.</description>
          <units>percentage of time in AF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="8.3"/>
                    <measurement group_id="O2" value="5.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last month of the intervention period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="8.1"/>
                    <measurement group_id="O2" value="5.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.440</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in AF Burden</title>
        <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last five months of the intervention period (the whole intervention period).</description>
        <time_frame>Comparing Baseline to the last five months of the intervention period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AF Burden</title>
          <description>Difference between PAP treatment and usual care in change of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last five months of the intervention period (the whole intervention period).</description>
          <units>percentage of time in AF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="8.3"/>
                    <measurement group_id="O2" value="5.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months intervention period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="6.4"/>
                    <measurement group_id="O2" value="4.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With More Than 25% Reduction in AF Burden</title>
        <description>Difference between PAP treatment and usual care in the proportion of patients with at least 25% reduction of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last three months of the intervention period.</description>
        <time_frame>Baseline to last three months of the intervention</time_frame>
        <population>The proportion of patients with at least 25% reduction in AF burden</population>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With More Than 25% Reduction in AF Burden</title>
          <description>Difference between PAP treatment and usual care in the proportion of patients with at least 25% reduction of AF burden (% of time in AF, as measured by loop recorder) from baseline (one month prior to randomization) to the last three months of the intervention period.</description>
          <population>The proportion of patients with at least 25% reduction in AF burden</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-9.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Recurrence Rate After Ablation, as Measured by Loop Recorder</title>
        <description>Change of recurrence rate after ablation, as measured by loop recorder, after 6 months post ablation and after 12 months post ablation.</description>
        <time_frame>12 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in AF Symptoms as Assessed by Atrial Fibrillation Severity Scale (AFSS)</title>
        <description>Change in AF symptoms between CPAP treatment and usual care. The questionnaire quantifies three domains of AF: event frequency (score 1-10), duration (score 1-10), and global episode severity (score 1-10). The total AF burden is calculated from the modified sum of the frequency, duration, and severity of AF (score 3-30, with higher scores indicating greater AF burden ). In addition, the AFSS assesses a symptom score based on seven items asking how bothered patients are by specified symptoms (score 0-35). Global well-being is a visual analogue scale ranging from 1 to 10 (10 indicating the best possible life).</description>
        <time_frame>6 months, 12 months and 18 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life (QoL) as Assessed by Medical Outcomes Study 36-item Short-Form Health Survey (SF-36)</title>
        <description>Difference between CPAP and usual care in QoL as assessed by SF36, Version 1.2. Item scores are transformed into the Physical and Mental Component Summary scores (PCS and MCS). Scores range from 0 to 100, with higher scores indicating a better health state.</description>
        <time_frame>Assessed at baseline, 6 months, 12 months and 18 months, baseline and 6 months reported.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life (QoL) as Assessed by Medical Outcomes Study 36-item Short-Form Health Survey (SF-36)</title>
          <description>Difference between CPAP and usual care in QoL as assessed by SF36, Version 1.2. Item scores are transformed into the Physical and Mental Component Summary scores (PCS and MCS). Scores range from 0 to 100, with higher scores indicating a better health state.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mental Component Summary score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" spread="9.5"/>
                    <measurement group_id="O2" value="52.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months Mental Component Summary score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="8.7"/>
                    <measurement group_id="O2" value="51.5" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Physical Component Summary score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="9.1"/>
                    <measurement group_id="O2" value="43.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months Physical Component Summary score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="10.2"/>
                    <measurement group_id="O2" value="45.9" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Summary score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Summary score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Quality and Symptoms of Sleep Apnea: Epworth Sleepiness Scale (ESS) Score</title>
        <description>Difference between PAP treatment and usual care in Change in daytime sleepiness as measured using the Epworth Sleepiness Scale (ESS) score, with scores ranging from 0 to 24 (most sleepy)</description>
        <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported</time_frame>
        <population>Baseline and 6 months reported</population>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Quality and Symptoms of Sleep Apnea: Epworth Sleepiness Scale (ESS) Score</title>
          <description>Difference between PAP treatment and usual care in Change in daytime sleepiness as measured using the Epworth Sleepiness Scale (ESS) score, with scores ranging from 0 to 24 (most sleepy)</description>
          <population>Baseline and 6 months reported</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="3.1"/>
                    <measurement group_id="O2" value="7.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="3.6"/>
                    <measurement group_id="O2" value="7.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symptoms of Obstructive Sleep Apnea Assessed by the Berlin Questionnaire.</title>
        <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the Berlin Questionnaire. Positive scores in two or more categories suggest a high risk of OSA.</description>
        <time_frame>6 months, 12 months and 18 months</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symptoms of Sleep Apnea Using the Functional Outcomes of Sleep Questionnaire (FOSQ)</title>
        <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the Functional Outcomes of Sleep Questionnaire (FOSQ). Score range is 5-20 Points, with higher scores indicating better functional status.</description>
        <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symptoms of Sleep Apnea Using the Functional Outcomes of Sleep Questionnaire (FOSQ)</title>
          <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the Functional Outcomes of Sleep Questionnaire (FOSQ). Score range is 5-20 Points, with higher scores indicating better functional status.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="1.9"/>
                    <measurement group_id="O2" value="17.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="2.0"/>
                    <measurement group_id="O2" value="17.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.850</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symptoms of Sleep Apnea Measured by the STOP-Bang</title>
        <description>Change in sleep quality and symptoms of obstructive sleep apnea as measured using the STOP-Bang Questionnaire. Score between 0-8. A score of â¥3 suggest risk for OSA.</description>
        <time_frame>6 months, 12 months and 18 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CRP</title>
        <description>Difference between PAP treatment and usual care in change of CRP</description>
        <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRP</title>
          <description>Difference between PAP treatment and usual care in change of CRP</description>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.8" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.7" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.8" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.650</p_value>
            <method>Regression, Linear</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction</title>
        <description>Difference between PAP treatment and usual care in change of left ventricular ejection fraction as assessed by ecco</description>
        <time_frame>6 months, 12 months and 18 months. Baseline and 6 months reported.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction</title>
          <description>Difference between PAP treatment and usual care in change of left ventricular ejection fraction as assessed by ecco</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="5.2"/>
                    <measurement group_id="O2" value="57.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follw up 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="4.2"/>
                    <measurement group_id="O2" value="56.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Cardiac Marker NT-proBNP.</title>
        <description>Difference between PAP treatment and usual care in change of Cardiac marker of NT-proBNP.</description>
        <time_frame>6 months, 12 months. Baseline and 6 months reported.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Cardiac Marker NT-proBNP.</title>
          <description>Difference between PAP treatment and usual care in change of Cardiac marker of NT-proBNP.</description>
          <units>ng/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="50" upper_limit="152.3"/>
                    <measurement group_id="O2" value="84" lower_limit="50" upper_limit="170.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.5" lower_limit="50.7" upper_limit="190.3"/>
                    <measurement group_id="O2" value="87" lower_limit="50" upper_limit="229.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.389</p_value>
            <method>Regression, Linear</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-103.4</ci_lower_limit>
            <ci_upper_limit>40.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine the Effect of SA Treatment on Gene Expression of White Blood Cells.</title>
        <description>Examine the effect of SA treatment on gene Expression of white blood cells. Is paroxysmal AF Associated with specific gene Expression patterns? Examine the influence of SA treatment on the pattern of gene Expression and if this is related to reduction of atrial fibrillation burden</description>
        <time_frame>6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine if Onset of Paroxysmal AF is Associated With Specific Activity Patterns, as Assessed by Garmin Vivofit2/3, Activity Recording</title>
        <description>Examine if onset of paroxysmal AF is Associated with specific Activity patterns, as assessed by garmin Vivofit2/3, Activity recording</description>
        <time_frame>6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Composition as Assessed by Bioelectric Impedance Analysis (BIA) (Tanita)</title>
        <description>Change in body composition (BMI) as assessed by Bioelectric Impedance Analysis (BIA) (Tanita)</description>
        <time_frame>Baseline to follow up 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAP-therapy (CPAP or ASV)</title>
            <description>PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No sleep apnea treatment (usual care)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Composition as Assessed by Bioelectric Impedance Analysis (BIA) (Tanita)</title>
          <description>Change in body composition (BMI) as assessed by Bioelectric Impedance Analysis (BIA) (Tanita)</description>
          <units>Kg/m Ì 2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="4.8"/>
                    <measurement group_id="O2" value="29.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="5.1"/>
                    <measurement group_id="O2" value="29.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.697</p_value>
            <method>Regression, Logistic</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Test as Assessed by Spirometry</title>
        <description>Lung function test as assessed by spirometry</description>
        <time_frame>Baseline, 6 months</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months (intervention period)</time_frame>
      <desc>Adverse event collection was obtained by regular investigator assessment, and data collection from the loop recorder (prolonged pauses).</desc>
      <group_list>
        <group group_id="E1">
          <title>CPAP-therapy</title>
          <description>Positive airway pressure therapy (CPAP)</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>No sleep apnea treatment</description>
        </group>
        <group group_id="E3">
          <title>ASV Therapy</title>
          <description>Adaptive Servo Ventilation (ASV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pacemaker implantation due to syncope and prolonged pauses</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization due to syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization due to symptomatic atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization due to chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to hemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Lars Gullestad</name_or_title>
      <organization>Oslo University Hospital</organization>
      <phone>+4797644772</phone>
      <email>lars.gullestad@medisin.uio.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

